Literature DB >> 10517606

Characterization of haemagglutinin activity of Clostridium botulinum type C and D 16S toxins, and one subcomponent of haemagglutinin (HA1).

Kaoru Inoue1, Yukako Fujinaga1, Koichi Honke2, Kenji Yokota1, Tetsuya Ikeda3, Tohru Ohyama3, Kouichi Takeshi3, Toshihiro Watanabe4, Katsuhiro Inoue4, Keiji Oguma1.   

Abstract

The 16S toxin and one subcomponent of haemagglutinin (HA), designated HA1, were purified from a type D culture of Clostridium botulinum by a newly established procedure, and their HA activities as well as that of purified type C 16S toxin were characterized. SDS-PAGE analysis indicated that the free HA1 forms a polymer with a molecular mass of approximately 200 kDa. Type C and D 16S toxins agglutinated human erythrocytes in the same manner. Their HA titres were dramatically reduced by employing erythrocytes that had been previously treated with neuraminidase, papain or proteinase K, and were inhibited by the addition of N-acetylneuraminic acid to the reaction mixtures. In a direct-binding test to glycolipids such as SPG (NeuAc alpha2-3Gal beta1-4GlcNAc beta1-3Gal beta1-4Glc beta1-Cer) and GM3 (NeuAc alpha2-3Gal beta1-4Glc beta1-Cer), and glycoproteins such as glycophorin A and/or B prepared from the erythrocytes, both toxins bound to sialylglycolipids and sialoglycoproteins, but bound to neither neutral glycolipids nor asialoglycoproteins. On the basis of these results, it was concluded that type C and D 165 toxins bind to erythrocytes through N-acetylneuraminic acid. HA1 showed no haemagglutination activity, although it did bind to sialylglycolipids. We therefore speculate that binding to glycoproteins rather than to glycolipids may be important in causing haemagglutination by type C and D 16S toxins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517606     DOI: 10.1099/00221287-145-9-2533

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  5 in total

1.  Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with dystonia.

Authors:  Hideyuki Arimitsu; Kaoru Inoue; Yoshihiko Sakaguchi; Jaechul Lee; Yukako Fujinaga; Toshihiro Watanabe; Tohru Ohyama; Robert Hirst; Keiji Oguma
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

2.  Involvement of ganglioside GM3 in G(2)/M cell cycle arrest of human monocytic cells induced by Actinobacillus actinomycetemcomitans cytolethal distending toxin.

Authors:  Koji Mise; Sumio Akifusa; Shinobu Watarai; Toshihiro Ansai; Tatsuji Nishihara; Tadamichi Takehara
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  Distinct roles for the N- and C-terminal regions in the cytotoxicity of pierisin-1, a putative ADP-ribosylating toxin from cabbage butterfly, against mammalian cells.

Authors:  T Kanazawa; M Watanabe; Y Matsushima-Hibiya; T Kono; N Tanaka; K Koyama; T Sugimura; K Wakabayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

4.  Vaccination with recombinant whole heavy chain fragments of Clostridium botulinum Type C and D neurotoxins.

Authors:  Hideyuki Arimitsu; Jae-Chul Lee; Yoshihiko Sakaguchi; Yuji Hayakawa; Michiko Hayashi; Miki Nakaura; Hikaru Takai; Song-Nan Lin; Masafumi Mukamoto; Tom Murphy; Keiji Oguma
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

5.  Distribution of cytotoxic and DNA ADP-ribosylating activity in crude extracts from butterflies among the family Pieridae.

Authors:  Yasuko Matsumoto; Tsuyoshi Nakano; Masafumi Yamamoto; Yuko Matsushima-Hibiya; Ken-Ichi Odagiri; Osamu Yata; Kotaro Koyama; Takashi Sugimura; Keiji Wakabayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-06       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.